𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adalimumab as therapy for fistulizing orofacial Crohn's disease

✍ Scribed by Glen Doherty; Roshni Kalachand; Stephen Patchett

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
117 KB
Volume
16
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Adalimumab for cutaneous metastatic Croh
Adalimumab for cutaneous metastatic Crohn's disease
✍ Didia Bismara Cury; Alan C. Moss; Geraldo Elias; Alexandre Nakao πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 124 KB πŸ‘ 2 views
Adherence to adalimumab therapy in Crohn
Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience
✍ Vincent Billioud; David Laharie; JΓ©rΓ΄me Filippi; Xavier Roblin; Abderrahim Oussa πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 179 KB πŸ‘ 1 views

Background: We evaluated adherence to adalimumab therapy in Crohn's disease (CD). Methods: This was an observational multicenter study conducted in four French university hospitals between April 4, 2008 and January 1, 2010. Patients were systematically asked, at each clinical visit, whether or not

Postoperative therapy for Crohn's diseas
Postoperative therapy for Crohn's disease
✍ Eric Blum; Jeffry A. Katz πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 118 KB

Prevention of the postoperative recurrence of Crohn's disease (CD) remains a challenging clinical problem. The majority of patients with CD will need surgery for treatment of the disease, most of these patients will develop recurrent symptoms within 5 years postoperatively, and many patients will ne

Adalimumab treatment for peristomal pyod
Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease
✍ Naim Alkhouri; Vera Hupertz; Lori Mahajan πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 3 views

PG) is an uncommon neutrophilic dermatosis first described by Brunsting et al in 1930. 1 It is a painful, chronic ulcerating inflammatory skin condition that appears to be immune-mediated. The characteristic lesion begins as small erythematous papules that rapidly spread concentrically, coalesce, an

Risk–benefit analysis of adalimumab vers
Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease
✍ Edward V. Loftus Jr; Scott J. Johnson; Si-Tien Wang; Eric Wu; Parvez M. Mulani; πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 474 KB πŸ‘ 1 views

Background: Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. Methods: A base-case analysis